acitretin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
retinol derivatives 78 55079-83-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • acitretin
  • acitretinoin
  • etretin
  • neotigason
  • soriatane
  • isoacitretin
  • isoetretin
An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of ETRETINATE with the advantage of a much shorter half-life when compared with etretinate.
  • Molecular weight: 326.44
  • Formula: C21H26O3
  • CLOGP: 6.07
  • LIPINSKI: 1
  • HAC: 3
  • HDO: 1
  • TPSA: 46.53
  • ALOGS: -5.83
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
35 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 3.83 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 59 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Oct. 28, 1996 FDA STIEFEL LABS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psoriasis 885.31 22.45 388 9003 92304 56190372
Skin haemorrhage 237.10 22.45 78 9313 8335 56274341
Skin exfoliation 185.40 22.45 100 9291 36800 56245876
Neurologic neglect syndrome 157.58 22.45 42 9349 2156 56280520
Carotid artery thrombosis 156.72 22.45 42 9349 2202 56280474
Respiratory tract congestion 131.08 22.45 60 9331 15531 56267145
Personality disorder 122.12 22.45 42 9349 5131 56277545
Sneezing 118.75 22.45 56 9335 15504 56267172
Sinus congestion 118.19 22.45 56 9335 15668 56267008
Sinus disorder 103.53 22.45 56 9335 20678 56261998
Sensory loss 103.15 22.45 43 9348 8892 56273784
Hemiplegia 102.28 22.45 42 9349 8362 56274314
Affect lability 97.97 22.45 43 9348 10082 56272594
Motor dysfunction 97.50 22.45 42 9349 9415 56273261
Adjustment disorder 92.27 22.45 28 9363 2295 56280381
Psoriatic arthropathy 89.69 22.45 84 9307 73924 56208752
Coordination abnormal 85.90 22.45 42 9349 12579 56270097
Rhinorrhoea 85.47 22.45 73 9318 56964 56225712
Eating disorder 73.88 22.45 42 9349 17063 56265613
Muscle spasticity 70.42 22.45 43 9348 19917 56262759
Hemiparesis 67.50 22.45 43 9348 21447 56261229
Cutaneous T-cell lymphoma 60.78 22.45 18 9373 1357 56281319
Cystitis 58.10 22.45 55 9336 48983 56233693
Erythrodermic psoriasis 57.48 22.45 16 9375 966 56281710
Aphasia 56.20 22.45 44 9347 30371 56252305
Skin plaque 55.74 22.45 26 9365 7012 56275664
Influenza 54.37 22.45 73 9318 95188 56187488
Infected dermal cyst 53.98 22.45 13 9378 441 56282235
Pustular psoriasis 53.19 22.45 22 9369 4456 56278220
Skin lesion 52.63 22.45 41 9350 28094 56254582
Rhesus antigen positive 51.06 22.45 10 9381 124 56282552
Rash pustular 50.87 22.45 24 9367 6639 56276037
Oral lichen planus 50.37 22.45 13 9378 587 56282089
Influenza like illness 49.79 22.45 56 9335 60932 56221744
Erythema 49.19 22.45 91 9300 155848 56126828
Pruritus 47.74 22.45 138 9253 316485 55966191
Drug ineffective 46.60 22.45 286 9105 918703 55363973
Dysarthria 44.27 22.45 43 9348 39507 56243169
Dry skin 43.22 22.45 46 9345 47063 56235613
Arterial occlusive disease 42.89 22.45 20 9371 5390 56277286
Gangrene 42.43 22.45 20 9371 5520 56277156
Squamous cell carcinoma 40.63 22.45 22 9369 8126 56274550
Angina pectoris 40.23 22.45 35 9356 27941 56254735
Guttate psoriasis 40.22 22.45 10 9381 388 56282288
Dysphagia 38.16 22.45 57 9334 81890 56200786
Weaning failure 36.85 22.45 9 9382 324 56282352
Wrong technique in device usage process 36.56 22.45 15 9376 2975 56279701
Lichen planus 34.09 22.45 13 9378 2129 56280547
Blood immunoglobulin M decreased 32.83 22.45 10 9381 829 56281847
Skin fissures 32.17 22.45 20 9371 9553 56273123
Blood albumin increased 32.06 22.45 10 9381 898 56281778
Burning sensation 31.94 22.45 40 9351 48656 56234020
Pain of skin 31.44 22.45 19 9372 8627 56274049
Oesophageal stenosis 29.88 22.45 13 9378 2980 56279696
Immunoglobulins decreased 29.85 22.45 10 9381 1127 56281549
Tongue ulceration 29.13 22.45 13 9378 3166 56279510
Palmoplantar pustulosis 28.90 22.45 8 9383 473 56282203
Type IIb hyperlipidaemia 28.77 22.45 5 9386 30 56282646
Ichthyosis 27.52 22.45 5 9386 40 56282636
Nasopharyngitis 27.35 22.45 90 9301 220869 56061807
Inflammatory bowel disease 27.02 22.45 13 9378 3755 56278921
Toxicity to various agents 26.95 22.45 3 9388 224561 56058115
Increased bronchial secretion 26.46 22.45 10 9381 1597 56281079
Oesophageal ulcer 25.86 22.45 13 9378 4126 56278550
Injection site bruising 25.83 22.45 32 9359 38489 56244187
Sunburn 25.14 22.45 11 9380 2557 56280119
Arthritis 25.07 22.45 53 9338 99799 56182877
Keratoacanthoma 24.79 22.45 7 9384 445 56282231
Skin atrophy 24.75 22.45 13 9378 4517 56278159
Swelling 24.67 22.45 5 9386 239766 56042910
Tanning 24.52 22.45 5 9386 77 56282599
Onychalgia 24.42 22.45 8 9383 841 56281835
Face oedema 24.36 22.45 22 9369 18430 56264246
Blood immunoglobulin G decreased 23.48 22.45 10 9381 2176 56280500
Rebound psoriasis 23.20 22.45 5 9386 102 56282574
Inappropriate schedule of product administration 22.98 22.45 46 9345 83341 56199335
Mean cell haemoglobin increased 22.58 22.45 10 9381 2390 56280286

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psoriasis 766.47 23.33 305 6204 46414 31644421
Drug ineffective 191.91 23.33 311 6198 395262 31295573
Vein rupture 187.38 23.33 41 6468 725 31690110
Skin plaque 172.87 23.33 54 6455 3961 31686874
Venous injury 108.16 23.33 22 6487 268 31690567
Pityriasis rubra pilaris 106.89 23.33 19 6490 104 31690731
Injection site haemorrhage 100.25 23.33 45 6464 9040 31681795
Erythrodermic psoriasis 89.56 23.33 23 6486 824 31690011
Injection site papule 83.52 23.33 18 6491 295 31690540
Psoriatic arthropathy 82.03 23.33 51 6458 19832 31671003
Cutaneous T-cell lymphoma 77.94 23.33 23 6486 1388 31689447
Dermatitis exfoliative generalised 77.78 23.33 28 6481 3171 31687664
Skin injury 76.74 23.33 24 6485 1763 31689072
Injection site swelling 74.73 23.33 38 6471 10049 31680786
Inappropriate schedule of product administration 70.14 23.33 68 6441 50755 31640080
Pain of skin 67.36 23.33 27 6482 4099 31686736
Therapeutic product effect incomplete 67.03 23.33 62 6447 43634 31647201
Hepatic fibrosis 62.03 23.33 25 6484 3849 31686986
Squamous cell carcinoma 61.37 23.33 34 6475 10677 31680158
Pruritus 59.27 23.33 98 6411 125069 31565766
Skin erosion 55.68 23.33 19 6490 1837 31688998
Drug intolerance 54.40 23.33 60 6449 51973 31638862
Granuloma annulare 53.92 23.33 11 6498 136 31690699
Hepatic cirrhosis 51.82 23.33 35 6474 15639 31675196
Hypercholesterolaemia 50.18 23.33 27 6482 8003 31682832
Squamous cell carcinoma of skin 49.43 23.33 29 6480 10145 31680690
Anti-cyclic citrullinated peptide antibody positive 48.39 23.33 16 6493 1404 31689431
Keratoacanthoma 47.72 23.33 13 6496 586 31690249
Phototherapy 47.06 23.33 8 6501 32 31690803
Joint ankylosis 44.27 23.33 14 6495 1066 31689769
Bone cyst 43.27 23.33 14 6495 1147 31689688
Pain in extremity 40.89 23.33 80 6429 116123 31574712
Treatment failure 40.83 23.33 46 6463 40746 31650089
Myalgia 39.92 23.33 63 6446 77195 31613640
Hyperkeratosis 37.90 23.33 17 6492 3403 31687432
Muscular weakness 34.67 23.33 54 6455 65394 31625441
Malignant melanoma stage I 34.35 23.33 7 6502 86 31690749
Basal cell carcinoma 34.23 23.33 29 6480 18150 31672685
Induration 33.95 23.33 11 6498 905 31689930
Osteolysis 33.85 23.33 14 6495 2301 31688534
Botryomycosis 33.57 23.33 6 6503 34 31690801
Hidradenitis 32.54 23.33 11 6498 1033 31689802
Neuroendocrine tumour of the lung metastatic 32.46 23.33 7 6502 115 31690720
Macule 31.79 23.33 11 6498 1108 31689727
Emotional distress 31.43 23.33 25 6484 14331 31676504
Skin exfoliation 31.13 23.33 31 6478 23843 31666992
Red blood cell sedimentation rate abnormal 30.26 23.33 14 6495 3008 31687827
Hand deformity 30.15 23.33 14 6495 3033 31687802
Retinal disorder 29.94 23.33 10 6499 905 31689930
Decreased immune responsiveness 28.68 23.33 11 6498 1484 31689351
Insomnia 27.12 23.33 60 6449 94776 31596059
Acute kidney injury 26.81 23.33 12 6497 279702 31411133
Toxicity to various agents 26.80 23.33 3 6506 181484 31509351
Alanine aminotransferase abnormal 26.65 23.33 14 6495 3953 31686882
Myasthenia gravis 26.40 23.33 14 6495 4029 31686806
Bone erosion 25.71 23.33 13 6496 3390 31687445
Erythema 25.43 23.33 53 6456 80352 31610483
Gastrointestinal infection 24.15 23.33 14 6495 4786 31686049
Gastrointestinal tube insertion 23.80 23.33 9 6500 1168 31689667
Diabetes mellitus 23.76 23.33 36 6473 42520 31648315
Hypereosinophilic syndrome 23.49 23.33 6 6503 210 31690625

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psoriasis 1435.48 19.03 593 14143 97840 70815868
Skin haemorrhage 231.31 19.03 85 14651 10095 70903613
Drug ineffective 201.48 19.03 533 14203 939219 69974489
Skin exfoliation 177.62 19.03 116 14620 48510 70865198
Skin plaque 165.88 19.03 66 14670 9717 70903991
Vein rupture 154.50 19.03 41 14695 1652 70912056
Neurologic neglect syndrome 145.10 19.03 42 14694 2339 70911369
Carotid artery thrombosis 142.32 19.03 42 14694 2504 70911204
Cutaneous T-cell lymphoma 124.90 19.03 38 14698 2515 70911193
Psoriatic arthropathy 120.36 19.03 103 14633 64668 70849040
Erythrodermic psoriasis 117.43 19.03 33 14703 1651 70912057
Respiratory tract congestion 111.46 19.03 60 14676 17593 70896115
Personality disorder 110.23 19.03 42 14694 5506 70908202
Squamous cell carcinoma 107.48 19.03 55 14681 14549 70899159
Pityriasis rubra pilaris 106.05 19.03 19 14717 108 70913600
Sneezing 102.53 19.03 56 14680 16895 70896813
Sinus congestion 101.24 19.03 56 14680 17317 70896391
Sinus disorder 99.35 19.03 57 14679 18902 70894806
Injection site haemorrhage 90.96 19.03 60 14676 25467 70888241
Affect lability 88.83 19.03 43 14693 10103 70903605
Venous injury 88.52 19.03 22 14714 680 70913028
Dermatitis exfoliative generalised 87.36 19.03 37 14699 6377 70907331
Sensory loss 86.92 19.03 44 14692 11375 70902333
Pruritus 84.62 19.03 207 14529 345353 70568355
Inappropriate schedule of product administration 83.17 19.03 107 14629 107448 70806260
Motor dysfunction 78.55 19.03 43 14693 13027 70900681
Adjustment disorder 77.91 19.03 28 14708 3116 70910592
Hemiplegia 73.40 19.03 42 14694 13853 70899855
Rhinorrhoea 72.83 19.03 79 14657 66292 70847416
Keratoacanthoma 72.19 19.03 20 14716 949 70912759
Skin lesion 71.08 19.03 61 14675 38399 70875309
Pain of skin 67.91 19.03 36 14700 10230 70903478
Coordination abnormal 67.75 19.03 42 14694 16024 70897684
Injection site papule 65.51 19.03 18 14718 828 70912880
Pustular psoriasis 63.91 19.03 27 14709 4623 70909085
Toxicity to various agents 63.64 19.03 4 14732 382168 70531540
Muscle spasticity 62.30 19.03 43 14693 19646 70894062
Eating disorder 62.19 19.03 42 14694 18523 70895185
Influenza 54.16 19.03 90 14646 113610 70800098
Erythema 53.54 19.03 124 14612 199439 70714269
Cystitis 53.46 19.03 57 14679 46884 70866824
Therapeutic product effect incomplete 53.27 19.03 92 14644 119790 70793918
Rhesus antigen positive 48.87 19.03 10 14726 124 70913584
Muscular weakness 48.67 19.03 96 14640 138240 70775468
Hemiparesis 44.58 19.03 43 14693 31426 70882282
Hyperkeratosis 44.49 19.03 24 14712 7060 70906648
Skin erosion 44.38 19.03 20 14716 3996 70909712
Aphasia 43.16 19.03 49 14687 43200 70870508
Squamous cell carcinoma of skin 43.15 19.03 29 14707 12683 70901025
Phototherapy 41.10 19.03 7 14729 28 70913680
Rash pustular 41.07 19.03 26 14710 10282 70903426
Induration 40.95 19.03 15 14721 1761 70911947
Oral lichen planus 40.46 19.03 12 14724 727 70912981
Granuloma annulare 39.04 19.03 11 14725 555 70913153
Onychalgia 39.00 19.03 12 14724 824 70912884
Joint ankylosis 38.97 19.03 14 14722 1555 70912153
Influenza like illness 37.00 19.03 56 14680 65275 70848433
Guttate psoriasis 36.89 19.03 10 14726 437 70913271
Acute kidney injury 36.81 19.03 27 14709 474597 70439111
Skin fissures 36.56 19.03 25 14711 11245 70902463
Infected dermal cyst 35.07 19.03 12 14724 1155 70912553
Rebound psoriasis 34.13 19.03 8 14728 192 70913516
Injection site swelling 33.42 19.03 43 14693 43114 70870594
Arthritis 33.25 19.03 67 14669 97913 70815795
Dry skin 33.18 19.03 49 14687 55882 70857826
Neuroendocrine tumour of the lung metastatic 32.32 19.03 7 14729 116 70913592
Arterial occlusive disease 32.03 19.03 20 14716 7722 70905986
Hypercholesterolaemia 31.97 19.03 28 14708 18089 70895619
Malignant melanoma stage I 31.47 19.03 7 14729 132 70913576
Myalgia 31.25 19.03 91 14645 167801 70745907
Skin injury 31.13 19.03 14 14722 2784 70910924
Nasopharyngitis 30.94 19.03 109 14627 222097 70691611
Bone cyst 30.77 19.03 14 14722 2860 70910848
Gangrene 30.73 19.03 20 14716 8289 70905419
Pain in extremity 30.57 19.03 142 14594 327940 70585768
Death 30.20 19.03 37 14699 510024 70403684
Hypotension 30.07 19.03 24 14712 404357 70509351
Dyslipidaemia 29.94 19.03 21 14715 9839 70903869
Immunoglobulins decreased 29.07 19.03 11 14725 1413 70912295
Macule 28.88 19.03 13 14723 2590 70911118
Weaning failure 28.73 19.03 9 14727 656 70913052
Wrong technique in device usage process 28.65 19.03 14 14722 3354 70910354
Neutropenia 28.46 19.03 9 14727 257147 70656561
Skin atrophy 28.27 19.03 16 14720 5163 70908545
Osteolysis 28.07 19.03 14 14722 3505 70910203
Skin disorder 27.94 19.03 33 14703 30324 70883384
Blood immunoglobulin M decreased 27.84 19.03 10 14726 1110 70912598
Type IIb hyperlipidaemia 27.67 19.03 5 14731 30 70913678
Dysphagia 26.87 19.03 67 14669 112767 70800941
Anaemia 26.34 19.03 27 14709 403396 70510312
Lichen planus 26.04 19.03 12 14724 2523 70911185
Palmoplantar pustulosis 25.98 19.03 8 14728 551 70913157
Blood albumin increased 25.46 19.03 10 14726 1420 70912288
Somnolence 24.85 19.03 7 14729 215599 70698109
Botryomycosis 24.66 19.03 5 14731 59 70913649
Cataract 23.78 19.03 42 14694 55603 70858105
Tanning 23.37 19.03 5 14731 78 70913630
Cutaneous symptom 23.35 19.03 7 14729 440 70913268
Inflammatory bowel disease 23.34 19.03 14 14722 5032 70908676
Burning sensation 22.71 19.03 40 14696 52830 70860878
Blood pressure increased 22.49 19.03 88 14648 188429 70725279
Psoriasis area severity index increased 21.83 19.03 5 14731 108 70913600
Infusion related reaction 21.70 19.03 7 14729 197527 70716181
Tongue ulceration 21.66 19.03 12 14724 3719 70909989
Dysarthria 21.59 19.03 43 14693 62270 70851438
Dehydration 21.56 19.03 10 14726 226132 70687576
Dizziness 21.34 19.03 40 14696 464101 70449607
Hepatic cirrhosis 21.29 19.03 29 14707 30702 70883006
Hidradenitis 21.13 19.03 11 14725 3011 70910697
Oesophageal stenosis 20.86 19.03 12 14724 3992 70909716
Hyponatraemia 20.82 19.03 4 14732 160083 70753625
Tonsil cancer 20.81 19.03 8 14728 1073 70912635
Thrombocytopenia 20.68 19.03 12 14724 239098 70674610
Ichthyosis 20.66 19.03 5 14731 138 70913570
Hepatic fibrosis 20.56 19.03 14 14722 6253 70907455
Cerebrovascular accident 20.49 19.03 71 14665 143399 70770309
Platelet count decreased 20.14 19.03 6 14730 178216 70735492
Seizure 20.10 19.03 6 14730 177956 70735752
Constipation 20.01 19.03 14 14722 252424 70661284
Tremor 20 19.03 4 14732 155620 70758088
Diffuse idiopathic skeletal hyperostosis 19.67 19.03 4 14732 48 70913660
Sunburn 19.41 19.03 11 14725 3560 70910148
Basal cell carcinoma 19.23 19.03 29 14707 33669 70880039
Decreased appetite 19.20 19.03 21 14715 304759 70608949

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D05BB02 DERMATOLOGICALS
ANTIPSORIATICS
ANTIPSORIATICS FOR SYSTEMIC USE
Retinoids for treatment of psoriasis
FDA CS M0018962 Retinoids
FDA EPC N0000175607 Retinoid
CHEBI has role CHEBI:50176 keratolytic drugs
MeSH PA D003879 Dermatologic Agents
MeSH PA D007641 Keratolytic Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Severe Recalcitrant Psoriasis indication
Lichen planus off-label use 4776004 DOID:9201
Keratosis follicularis off-label use 48611009 DOID:2734
Lamellar ichthyosis off-label use 205550003
Ichthyosiform erythroderma off-label use 268282005
Primary cutaneous T-cell lymphoma off-label use 400122007
Alcoholism contraindication 7200002
Hypercholesterolemia contraindication 13644009
Depressive disorder contraindication 35489007
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Night blindness contraindication 65194006 DOID:8499
Benign intracranial hypertension contraindication 68267002 DOID:11459
Diabetes mellitus contraindication 73211009 DOID:9351
Premature epiphyseal closure contraindication 89493005
Liver function tests abnormal contraindication 166603001
Hypoalphalipoproteinemia contraindication 190785000
Acute pancreatitis contraindication 197456007 DOID:2913
Hypertrophy of bone contraindication 203514008 DOID:205
Drug-induced hepatitis contraindication 235876009
Pregnancy, function contraindication 289908002
Hypertriglyceridemia contraindication 302870006
Cardiovascular event risk contraindication 395112001
Visual impairment contraindication 397540003
Breastfeeding (mother) contraindication 413712001
Obesity contraindication 414916001 DOID:9970
Psychiatric Disturbance contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.17 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Retinoic acid receptor alpha Nuclear hormone receptor AGONIST WOMBAT-PK CHEMBL
Retinoic acid receptor gamma Nuclear hormone receptor AGONIST CHEMBL CHEMBL
Bile salt export pump Transporter IC50 4.74 CHEMBL
Bile salt export pump Transporter IC50 4.71 CHEMBL

External reference:

IDSource
4021061 VUID
N0000148524 NUI
D02754 KEGG_DRUG
16818 RXNORM
C0050559 UMLSCUI
CHEBI:50173 CHEBI
CHEMBL1131 ChEMBL_ID
DB00459 DRUGBANK_ID
D017255 MESH_DESCRIPTOR_UI
5284513 PUBCHEM_CID
7598 IUPHAR_LIGAND_ID
5530 INN_ID
LCH760E9T7 UNII
004121 NDDF
108914001 SNOMEDCT_US
386938006 SNOMEDCT_US
4021061 VANDF
69427-46-9 SECONDARY_CAS_RN
11379 MMSL
117161 MMSL
4128 MMSL
d03836 MMSL

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0093-1135 CAPSULE 10 mg ORAL ANDA 24 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0093-1135 CAPSULE 10 mg ORAL ANDA 24 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0093-1135 CAPSULE 10 mg ORAL ANDA 24 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0093-1136 CAPSULE 25 mg ORAL ANDA 24 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0093-1136 CAPSULE 25 mg ORAL ANDA 24 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0093-1136 CAPSULE 25 mg ORAL ANDA 24 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0093-1138 CAPSULE 17.50 mg ORAL ANDA 24 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0093-1138 CAPSULE 17.50 mg ORAL ANDA 24 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0093-1138 CAPSULE 17.50 mg ORAL ANDA 24 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0115-1750 CAPSULE 10 mg ORAL ANDA 17 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0115-1751 CAPSULE 17.50 mg ORAL ANDA 17 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0115-1752 CAPSULE 22.50 mg ORAL ANDA 17 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0115-1753 CAPSULE 25 mg ORAL ANDA 17 sections
SORIATANE HUMAN PRESCRIPTION DRUG LABEL 1 0145-0090 CAPSULE 10 mg ORAL NDA 27 sections
SORIATANE HUMAN PRESCRIPTION DRUG LABEL 1 0145-0091 CAPSULE 25 mg ORAL NDA 27 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0378-7020 CAPSULE 10 mg ORAL ANDA 28 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0378-7020 CAPSULE 10 mg ORAL ANDA 28 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0378-7023 CAPSULE 25 mg ORAL ANDA 28 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0378-7023 CAPSULE 25 mg ORAL ANDA 28 sections
ACITRETIN HUMAN PRESCRIPTION DRUG LABEL 1 42291-086 CAPSULE 10 mg ORAL ANDA 25 sections
ACITRETIN HUMAN PRESCRIPTION DRUG LABEL 1 42291-087 CAPSULE 17.50 mg ORAL ANDA 25 sections
ACITRETIN HUMAN PRESCRIPTION DRUG LABEL 1 42291-088 CAPSULE 25 mg ORAL ANDA 25 sections
ACITRETIN HUMAN PRESCRIPTION DRUG LABEL 1 42794-080 CAPSULE 10 mg ORAL ANDA 25 sections
ACITRETIN HUMAN PRESCRIPTION DRUG LABEL 1 42794-081 CAPSULE 17.50 mg ORAL ANDA 25 sections
ACITRETIN HUMAN PRESCRIPTION DRUG LABEL 1 42794-083 CAPSULE 25 mg ORAL ANDA 25 sections
ACITRETIN HUMAN PRESCRIPTION DRUG LABEL 1 66993-894 CAPSULE 10 mg ORAL NDA authorized generic 16 sections
ACITRETIN HUMAN PRESCRIPTION DRUG LABEL 1 66993-896 CAPSULE 25 mg ORAL NDA authorized generic 16 sections